Get started
Author

Avinash Kumar

ORCID: 0009-0008-2419-0263
Observed ORCID: 0009-0008-2419-0263
OpenAlex ID: A5103361931
A Comprehensive Review on Pharmacotherapeutics of Herbal Bioenhancers
2012 · Ghanshyam B. Dudhatra, Shailesh K. Mody, et al. · The Scientific World JOURNAL · 227
PDF
Development and validation of a highly sensitive LC‐MS/MS‐ESI method for the determination of nobiletin in rat plasma: application to a pharmacokinetic study
2012 · Avinash Kumar, V. C. Devaraj, et al. · Biomedical Chromatography · 22
Herbal Antibacterials: A Review
2012 · Chirag Modi, Shailesh Mody, et al. · Journal of Intercultural Ethnopharmacology · 18
Development of an LC‐MS/MS method for determination of bicalutamide on dried blood spots: application to pharmacokinetic study in mice
2014 · Suresh P. S., S. Vijay Kumar, et al. · Biomedical Chromatography · 16
Exploration of inhibition potential of isoniazid and its metabolites towards CYP2E1 in human liver microsomes through LC-MS/MS analysis
2021 · Ankit Balhara, Avinash Kumar, et al. · Journal of Pharmaceutical and Biomedical Analysis · 11
Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration
2012 · G.B. Dudhatra, Avinash Kumar, et al. · Journal of Pharmacological and Toxicological Methods · 6
Preclinical assessment of Orteronel®, a CYP17A1 enzyme inhibitor in rats
2014 · Mohd Zainuddin, A. B. Vinod, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 5
Ultraperformance Liquid Chromatography Tandem Mass Spectrometry Assay of DNA Cytosine Methylation Excretion from Biological Systems
2025 · Yiming Liu, Jing Qu, et al. · ACS Omega · 4
Development and validation of an RP‐HPLC method for the quantitation of Orteronel (TAK‐700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study
2013 · Avinash Kumar, Vijay Kumar S, et al. · Biomedical Chromatography · 1
A Simple and Sensitive LC–MS/MS Method for Simultaneous Quantification of Dasatinib and Erythromycin in Mice Plasma: Application to Preclinical Pharmacokinetic Study
2026 · Avinash Kumar, Nirbhay Kumar Tiwari, et al. · Biomedical Chromatography
Abstract 5177: Exceptionally selective and orally bioavailable p300 degraders for the treatment of CBP-mutant and p300-dependent cancers
2026 · Iram Khan Iqbal, Krishna Chaitanya T, et al. · Cancer Research
Single-pot chemoselective barcoding system enables orthogonal quantification of DNA in RNA preparations
2025 · Jing Qu, Avinash Kumar, et al. · Microchemical Journal
Breast Cancer Diagnosis and Prognosis: Evaluating the Synergy of Feature Selection and Machine Learning Classifiers
2025 · Samarth Agarwal, Dheeraj Baghel, et al. · Smart innovation, systems and technologies
Abstract 3303: Paralogue selective p300 degraders induce synthetic lethality in pre-clinical models of CBP-deficient and p300-dependent malignancies
2024 · Saravanan Thiyagarajan, Chandrasekhar Abbineni, et al. · Cancer Research
Abstract A047: Discovery of potent and paralog selective PROTAC degraders of CBP or p300 proteins for the treatment of various cancers
2023 · Chandrasekhar Abbineni, Saravanan Thiyagarajan, et al. · Molecular Cancer Therapeutics
Abstract 4114: Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
2022 · Chandrasekhar Abbineni, Saravanan Thiyagarajan, et al. · Cancer Research
Development and validation of an LC‐MS/MS‐ESI method for the determination of lorglumide, a CCK‐1 antagonist in mouse plasma: application to a pharmacokinetic study
2011 · Kuldeep Sharma, Anitha Police, et al. · Biomedical Chromatography
Works count: 17
Citation count: 310
H-index: 6
I10-index: 5
Year
Topic
Type